Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Gyre Therapeutics (GYRE) over the last 10 years, with Dec 2024 value amounting to $61.5 million.

  • Gyre Therapeutics' Other Operating Expenses fell 100.01% to -$1,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $46.1 million, marking a year-over-year increase of 11.80%. This contributed to the annual value of $61.5 million for FY2024, which is 2367.10% up from last year.
  • As of FY2024, Gyre Therapeutics' Other Operating Expenses stood at $61.5 million, which was up 2,367.10% from -$2.7 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Other Operating Expenses registered a high of $61.5 million during FY2024, and its lowest value of -$2.7 million during FY2023.
  • Moreover, its 3-year median value for Other Operating Expenses was $57.2 million (2022), whereas its average is $38.6 million.
  • Per our database at Business Quant, Gyre Therapeutics' Other Operating Expenses plummeted by 104.74% in 2023 and then spiked by 2,367.10% in 2024.
  • Gyre Therapeutics' Other Operating Expenses (Yearly) stood at $9.2 million in 2020, then decreased by 19.46% to $7.4 million in 2021, then soared by 674.88% to $57.2 million in 2022, then tumbled by 104.74% to -$2.7 million in 2023, then soared by 2,367.10% to $61.5 million in 2024.